Liver Disease and Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
J Med Econ. 2012;15(1):112-24. doi: 10.3111/13696998.2011.632463. Epub 2011 Nov 4.
Thrombocytopenia (TCP), defined as platelet counts <150,000/µL, is a common complication of severe chronic liver disease (CLD). This retrospective study estimated the prevalence of thrombocytopenia in a large population of CLD patients and compared medical resource utilization and medical care costs by TCP status.
A retrospective analysis was conducted on a longitudinal administrative claims database from a large US commercial health plan. Patients assigned CLD diagnosis codes from January 1, 2000-December 31, 2003 were identified; annual ambulatory visits, ER visits, inpatient stays, and general and CLD-related medical care costs for patients with vs without TCP (identified using diagnosis codes and platelet count data if available) were compared.
Of 56,445 patients with an ICD-9-CM diagnosis for CLD, 1289 (2.3%) had a diagnosis for TCP. CLD patients with vs without a TCP diagnosis had >2.5-times the annual number of liver disease-related ambulatory visits (3.6 vs 1.4; odds ratio [OR] = 2.6, p < 0.01); were 13-times more likely to have a liver-related inpatient stay (OR = 13.0, p < 0.01); were nearly 4-times more likely to have a liver-related ER visit (OR = 3.9, p < 0.01); had 3.5-fold greater mean annual overall medical care costs ($43,560 vs $12,270, p < 0.01); and had 7-fold greater annual liver disease-related medical care costs ($9940 vs $1420, p < 0.01). Similar results were seen for patients with platelet count data indicating TCP.
CLD and TCP are not always diagnosed, nor is diagnosis uniform or standardized; administrative claims data are subject to coding errors, and individuals covered are not necessarily representative of the general US population. The number of CLD patients in this study with TCP (n = 1289) is small relative to that expected in the general US population.
In this analysis, CLD patients with TCP used significantly more medical resources and incurred significantly higher medical care costs than those without TCP.
血小板减少症(TCP)定义为血小板计数<150,000/µL,是严重慢性肝病(CLD)的常见并发症。本回顾性研究估计了大量 CLD 患者中 TCP 的患病率,并比较了 TCP 状态下的医疗资源利用和医疗保健费用。
对来自美国大型商业健康计划的纵向行政索赔数据库进行回顾性分析。确定 2000 年 1 月 1 日至 2003 年 12 月 31 日期间分配 CLD 诊断代码的患者;比较有 TCP(如果有诊断代码和血小板计数数据,则使用这些数据确定)和无 TCP 患者(无 TCP 患者)的年度门诊就诊、急诊就诊、住院和一般及 CLD 相关医疗保健费用。
在患有 ICD-9-CM 慢性肝病诊断的 56445 名患者中,有 1289 名(2.3%)患有 TCP 诊断。与无 TCP 诊断的 CLD 患者相比,有 TCP 诊断的 CLD 患者的年度肝病相关门诊就诊次数多 2.5 倍(3.6 次 vs 1.4 次;比值比[OR] = 2.6,p<0.01);发生与肝脏相关的住院治疗的可能性高 13 倍(OR = 13.0,p<0.01);发生与肝脏相关的急诊就诊的可能性高近 4 倍(OR = 3.9,p<0.01);年度总体医疗保健费用高 3.5 倍($43560 美元 vs $12270 美元,p<0.01);与肝脏疾病相关的年度医疗保健费用高 7 倍($9940 美元 vs $1420 美元,p<0.01)。对于有血小板计数数据表明存在 TCP 的患者,也观察到了类似的结果。
CLD 和 TCP 并非总是被诊断,诊断也并非总是一致或标准化;行政索赔数据容易出现编码错误,所涵盖的个体不一定代表美国一般人群。在这项研究中,患有 TCP 的 CLD 患者(n = 1289)的数量相对较少,与美国一般人群中预期的数量相比。
在这项分析中,与无 TCP 的患者相比,患有 TCP 的 CLD 患者使用了更多的医疗资源,并产生了更高的医疗保健费用。